Cross-reactivity between *Parietaria judaica* and *Parietaria officinalis* in immunotherapy extracts for the treatment of allergy to *Parietaria*

NATALY CANCELLIERE¹, IRENE IGLESIAS², ÁNGEL AyUGA¹ and ERNESTO ENRIqUE MIRANDA²

¹Medical Department, MERCK SLU, 28006 Madrid; ²Department of Allergology, Hospital of Sagunto, 46520 Valencia, Spain

Received July 11, 2019; Accepted January 2, 2020

DOI: 10.3892/br.2020.1297

Abstract. *Parietaria judaica* and *P. officinalis* are the two most common subspecies of the *Parietaria* genus. *P. judaica* and *P. officinalis* have exhibited cross-reactivity in previous studies. *P. judaica* pollen is the main cause of allergy in the Mediterranean area. It has been shown that a high percentage of patients sensitized to *P. judaica* with allergic rhinitis (AR) have an increased risk of developing asthma. The present study aimed to confirm the cross-reactivity between *P. judaica* and *P. officinalis* and to evaluate the use of a single *P. officinalis* extract in patients allergic to both subspecies as a preferable option for the diagnosis and treatment of allergy in a highly pollinated area of the Spanish Mediterranean coast. The present study was a single centre, observational cross-sectional study of adult patients diagnosed with AR and/or bronchial asthma who were sensitized to *Parietaria* pollen. A total of 24 patients were enrolled in the study and included in the analysis. Allergovit® immunotherapy extracts were selected for the study based on the protein content (*P. officinalis* pollen extract). The results of an *in vitro* ELISA revealed that 79.1% (n=19) of the patient sera were reactive to immunotherapy extracts. ELISA inhibition assay of the IgE binding to *P. officinalis* demonstrated inhibition values >70% in the sera of highly reactive patients, confirming the cross-reactivity between the two *Parietaria* subspecies. In addition, all patients enrolled in the study exhibited double skin positivity against *P. judaica* and *P. officinalis* extracts, as assessed by the skin prick test, further supporting the *in vivo* reactivity between the two subspecies. The present study demonstrated that *P. judaica* and *P. officinalis* pollen extracts were highly cross-reactive, and that a unique *P. officinalis* pollen extract may be used for the diagnosis and immunotherapy of patients allergic to *Parietaria*.

Introduction

Allergic rhinitis (AR) is a symptomatic disorder of the nose induced by an IgE-mediated inflammation following allergen exposure of the membranes lining the nose (1). Due to its increasing prevalence worldwide (2,3), including up to 22% in Spain (3,4), and the burden of symptoms impacting on the general well-being and health-related quality of life of patients suffering from this condition, AR represents a serious global health problem (5). AR and asthma frequently coexist, sharing a number of physiopathologic links and risk factors, including sensitization to allergens, total IgE levels and a family history of asthma (6). Between 20 and 50% of patients with AR have asthma (6,7), and AR has been demonstrated to occur in ≥80% of patients with asthma (8). Previous studies have consequently questioned whether both diseases may represent different expressions of a same underlying genetic predisposition (9-13).

*Parietaria* is a genus of the wind-pollinated dicotyledonous weeds of the Urticaceae family, which is predominantly widespread in several areas of southern Europe (14). *Parietaria* includes several subspecies, of which *P. judaica* and *P. officinalis* are the most common. *P. judaica* grows mainly on the Mediterranean coasts of Spain, southern France, Italy and Greece, whereas *P. officinalis* can be more frequently located in northern Italy, central France and central and eastern Europe (14). *P. judaica* in the Mediterranean area has a very long pollination period, reaching peaks in the spring and autumn (15).

*P. judaica* pollen has been identified to be the main cause of allergy in the Mediterranean area (16). In a study conducted in Catalonia, Spain, 47.8% of patients with AR due to *P. judaica* also suffered from asthma (11). In addition, in a retrospective cohort study conducted in Italy, sensitization to *P. judaica* significantly increased the risk of developing asthma in patients with AR, whereas no associations for other types of pollens were identified (17).

The composition of the allergenic extracts of the *P. judaica* pollen has been extensively studied and molecularly cloned, and the two major allergens (*Par j 1* and *Par j 2*) have been sequenced and characterized (18-21). *Par j 1* and *Par j 2* allergens are polypeptides of 14.7 and 11.3 kDa, respectively, that belong to the non-specific lipid transfer protein (20-22). The allergens share certain common structural similarities, as well as the same IgE binding epitopes (21). However, although the...
Par j 2 allergen has been recognized as the species-specific allergen marker of *P. judaica* sensitization (22), the full allergenic role and contribution of the two Pars have not been completely elucidated.

Resemblance and cross-reactivity of the two main subspecies of *Parietaria*, *P. judaica* and *P. officinalis*, have been confirmed in several studies (23-26). Bonura et al (25) demonstrated that the cross-reactivity between the two subspecies was due to the presence of the Par j 1 and Par j 2 allergens in the extracts with a high conserved IgE epitope content; all patients enrolled in their study exhibited a double-positive skin prick test (SPT) toward the *P. judaica* and *P. officinalis* extracts with similar IgE concentrations for both subspecies. In addition, ELISA inhibition experiments were performed to validate these results, thus demonstrating that the major *P. judaica* allergens inhibited most of the *P. judaica*- and *P. officinalis*-specific IgE in similar proportions (25). These results were confirmed in the study conducted by Patriarca et al (26), demonstrating that *P. officinalis* and *P. judaica* pollen extracts were completely cross-reactive. In addition, they revealed that one unique extract of *P. officinalis* was suitable for the in vivo diagnosis and immunotherapy of the patients allergic to *Parietaria* tested in the study (26).

Considering the above findings, the present study aimed to confirm that the use of a single *P. officinalis* extract in patients allergic to *P. judaica* and *P. officinalis* may be a suitable option for the diagnosis and treatment of patients sensitized to *Parietaria* in a high pollinated area of the Spanish Mediterranean coast.

**Materials and methods**

**Study Design.** It was a single centre, single visit, observational, cross-sectional study of adult patients diagnosed with AR and/or bronchial asthma sensitized to *Parietaria* pollen. The principal objective of the study was to assess the in vitro cross-reactivity between allergens present in *P. judaica* and *P. officinalis*. The secondary objective was to compare in vitro reactivities between *P. judaica* and *P. officinalis* in allergic patients sensitized to *Parietaria*.

Patients treated at the Hospital of Sagunto in a highly exposed to *Parietaria* pollen area of the Spanish Mediterranean coast (Levante) were included in the study from March to November 2017. Data were obtained either from the medical record or from a single visit that matched a routine consultation with a clinician, without interfering with the routine clinical practice. No therapeutic and/or diagnostic interventions were applied. Written informed consent was obtained from all study participants, and ethical approval was obtained from the Ethics Committee of Clinical Research at the Hospital of Sagunto (Valencia, Spain).

**Patients.** Patients eligible for this study had to fulfil all of the following inclusion criteria: i) Age, ≥18 years; ii) diagnosed with AR and/or bronchial asthma and sensitized to *P. judaica* pollen; and iii) without any previous specific immunotherapy treatment for allergy to *Parietaria*. In addition, the patients underwent at least a 7-day period without of antihistamines and glucocorticoids prior to the study. The exclusion criteria were as follows: i) Patients with any clinical conditions preventing them from understanding the implications and requirements of the study; ii) patients polysensitized to profilins; and iii) patients under other simultaneous immunotherapy treatment during the study follow-up period.

**Study variables.** For the primary objective analysis, in vitro reactivity of patient sera (allergy-specific IgE levels) to immunotherapy extracts (*P. officinalis*) were determined by ELISA. Two different immunotherapy treatments were tested: 3 ml (10,000 UT/ml) Allergovit® (Allergopharma; Merck KGaA) and 2.5 ml (1,000 DPP/ml) Depigoid® (Laboratorios Leti, S.L.). Protein extracts of the immunotherapy products were obtained by incubation with 10 mM PBS and 150 mM NaCl for 1 h at 4°C. The supernatant was dialyzed against H₂O and lyophilized. Subsequently, protein content was precipitated with 10% trichloroacetic acid, and the pellet was washed with cold acetone. The Bradford protein assay was used to quantify the protein content of the immunotherapy products.

**ELISA.** The reactivity of the sera was determined by ELISA assays produced in the laboratory of the Biotechnology and Plants Genomic Center at Polytechnic University of Madrid. Immunotherapy products were coated on ELISA plates at 50 µg/ml diluted in PBS for 2 h at 37°C. Following blocking for 1 h at room temperature with blocking buffer (Sigma-Aldrich; Merck KGaA), the plates were washed with PBS-0.05% Tween-20 and incubated with serum samples diluted 1:3 in PBS. The presence of the IgE was detected by incubation with horseradish peroxidase (HRP)-conjugated anti-IgE antibodies (1:3,000; cat. no. A9667; Sigma-Aldrich; Merck KGaA) for 1 h at room temperature and revealed with OPD substrate (Thermo Fisher Scientific, Inc.). Optical density (OD) was measure at 450 nm in a microplate reader. OD values were counted as positive if they exceeded the mean OD of the negative controls by >3 standard deviations (i.e., values >0.132). Positive values corresponded to reactive sera, whereas negative values corresponded to sera that were not considered reactive. Subsequently, cross-reactivity between allergens from *P. judaica* and *P. officinalis* (Allergovit®) pollen extracts was measured by the ELISA inhibition method.

**ELISA inhibition.** Sera of the patients exhibiting high reactivity to the sample (i.e. the highest OD values determined by the ELISA method) were selected for ELISA inhibition and were used as a reference of the index of stimulation of the sera without inhibition. The sera were inhibited by incubation with 30 µg pollen protein extract from *P. judaica*. Immunotherapy protein extracts were coated on ELISA plates (50 µg/ml) and following blocking as described above, the plates were incubated with serum samples inhibited with pollen protein extract of *P. judaica* and developed with anti IgE-HRP antibodies and OPD substrate. ELISA experiments were performed at the Biotechnology and Plants Genomic Center at Polytechnic University of Madrid (Madrid, Spain).

To analyse the protein content of the extracts, the samples were analysed by SDS-PAGE and Coomassie staining. Briefly, SDS-PAGE was performed using a 15% polyacrylamide gel and 0.1% SDS under reducing conditions with 2-mercaptoethanol. Proteins were visualised by staining with 0.25% Brilliant blue R250 (cat. no. B0149’ Sigma-Aldrich; Merck KGaA), 9%
acetic acid and 50% methanol by agitation on a shaker for 30 min at room temperature. Coomassie brilliant blue staining was removed using a destaining solution (40% methanol and 7% acetic acid) with gentle agitation at room temperature until the protein bands were visible.

For the secondary objective analysis, a SPT was performed to compare the in vivo reactivities between the two Parietaria subspecies in allergic patients sensitized to Parietaria by evaluating the specific mean IgE levels to P. judaica and P. officinalis and the total mean IgE levels obtained either from the patient medical records or a regular visit to the clinician. In addition, associations between the variables measured by the SPT for P. judaica and P. officinalis were analysed. Patients underwent SPT with P. judaica (ALK-Abelló®) and P. officinalis (Allergopharma®) aeroallergen plus a positive and negative control placed on the skin ≥2 cm apart. The positive control was 10 mg/ml histamine dichloride, and the negative control was glycerinated saline histamine at the same concentration. Test reading was performed at 15 min.

**Statistical analysis.** Statistical analyses were performed using SPSS version 22.0 (IBM Corp.). Sample size was calculated based on the necessary number of patients to achieve the primary objective (in vitro cross-reactivity between allergens present in P. judaica and P. officinalis). The sample size of the present study was calculated based on the results of a previous study that identified a significant correlation (r=0.98; P<0.0001) between patient sera specific IgE levels for P. judaica and P. officinalis with a sample of 30 patients (26).

For the overall descriptive analysis, quantitative variables were presented as the mean ± SD or median with first quartile (q1), third quartile (q3), minimum and maximum. Qualitative variables were described with absolute and relative frequencies with the valid percentages (percentages that do not include missing data) and total percentages (the sum of the valid responses plus the missing values). In cases where these two percentages had different values, the valid percentage was reported. Absent data were left as missing values.

Bivariate analyses with the parametric paired-sample t-test were performed to assess the secondary objective, assuming a normal distribution of the sample continuous variables. The 95% confidence intervals (CI) were estimated when required. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Patients.** A total of 24 patients meeting all the inclusion criteria entered the study and were included in the analysis. The mean

| Patient no. | Bronchial asthma diagnosis | Atopy | SPT: P. judaica (D+d)/2, mm | SPT: P. officinalis (D+d)/2, mm |
|-------------|---------------------------|-------|---------------------------|-------------------------------|
| 1           | No                        | Yes   | 8.00                      | 6.50                          |
| 2           | Yes                       | Yes   | 14.00                     | 13.50                         |
| 3           | Yes                       | Yes   | 10.00                     | 11.00                         |
| 4           | No                        | Yes   | 8.50                      | 7.50                          |
| 5           | No                        | Yes   | 16.00                     | 10.00                         |
| 6           | No                        | Yes   | 8.50                      | 8.50                          |
| 7           | No                        | Yes   | 10.00                     | 9.00                          |
| 8           | Yes                       | Yes   | 7.00                      | 6.50                          |
| 9           | No                        | Yes   | 13.50                     | 12.00                         |
| 10          | Yes                       | Yes   | 10.00                     | 7.00                          |
| 11          | Yes                       | Yes   | 6.50                      | 7.50                          |
| 12          | Yes                       | Yes   | 11.00                     | 10.50                         |
| 13          | No                        | Yes   | 8.50                      | 9.50                          |
| 14          | Yes                       | Yes   | 10.00                     | 9.50                          |
| 15          | No                        | Yes   | 4.50                      | 4.00                          |
| 16          | No                        | Yes   | 10.00                     | 8.00                          |
| 17          | No                        | Yes   | 10.00                     | 9.50                          |
| 18          | No                        | Yes   | 8.50                      | 5.00                          |
| 19          | Yes                       | Yes   | 7.50                      | 7.00                          |
| 20          | No                        | Yes   | 13.50                     | 8.50                          |
| 21          | Yes                       | Yes   | 11.50                     | 9.00                          |
| 22          | No                        | Yes   | 12.00                     | 11.00                         |
| 23          | No                        | Yes   | 12.00                     | 9.00                          |
| 24          | Yes                       | Yes   | 7.50                      | 8.50                          |

SPT, skin prick test; P., Parietaria; D, longest wheal diameter; d, longest diameter perpendicular to D.
The age of the participants was 40 years (range, 26-67 years), and 37.5% of the patients were female. All patients suffered from AR and 41.7% (n=10) were diagnosed with bronchial asthma. None of the patients presented comorbidities, such as diabetes or arterial hypertension, and 22.7 and 25% were regarded as current smokers or daily alcohol drinkers, respectively. Table I displays the clinical characteristics of each patient included in the study.

**Table II. SPT of in vivo reactivities between two Parietaria subspecies in allergic patients sensitised to Parietaria.**

| SPT result | Mean (95% CI) | SD | Median | Minimum | Maximum | Q1 | Q3 | N |
|------------|---------------|----|--------|---------|---------|----|----|---|
| Positive control (histamine) | | | | | | | | |
| D, mm      | 8.8 (7.8-9.8) | 2.4 | 8.0    | 5.0     | 17.0    | 7.3 | 10.0 | 24 |
| d, mm      | 6.5 (5.8-7.1) | 1.5 | 6.0    | 4.0     | 1       | 5.0 | 7.8  | 24 |
| (D+d)/2, mm| 7.7 (7.0-7.1) | 1.7 | 7.0    | 5.0     | 12.5    | 6.6 | 9.0  | 24 |
| Negative control | | | | | | | | |
| D, mm      | 0.0 (-)       | 0.0 | 0.0    | 0.0     | 0.0     | 0.0 | 0.0  | 24 |
| d, mm      | 0.0 (-)       | 0.0 | 0.0    | 0.0     | 0.0     | 0.0 | 0.0  | 24 |
| (D+d)/2, mm| 0.0 (-)       | 0.0 | 0.0    | 0.0     | 0.0     | 0.0 | 0.0  | 24 |
| Parietaria Judaica | | | | | | | | |
| D, mm      | 11.8* (10.4-13.3) | 3.4 | 11.0   | 5.0     | 19.0    | 10.0 | 15.0 | 24 |
| d, mm      | 7.6* (6.7-8.4) | 2.0 | 7.0    | 4.0     | 12.0    | 6.3  | 9.0  | 24 |
| (D+d)/2, mm| 10.0* (8.8-11.1) | 2.7 | 10.0   | 4.5     | 16.0    | 8.1  | 11.9 | 24 |
| Parietaria officinalis | | | | | | | | |
| D, mm      | 10.4 (9.1-11.7) | 3.1 | 10.0   | 5.0     | 18.0    | 9.0  | 12.0 | 24 |
| d, mm      | 7.0 (6.2-7.7)  | 1.8 | 6.0    | 3.0     | 10.0    | 6.0  | 8.8  | 24 |
| (D+d)/2, mm| 8.7 (7.8-9.6)  | 2.2 | 8.8    | 4.0     | 13.5    | 7.1  | 9.9  | 24 |

*P<0.05 vs. Parietaria officinalis. SPT, skin prick test; Q1, first quartile; Q3, third quartile; D, longest wheal diameter; d, longest diameter perpendicular to D.

**Figure 1.** ELISA reactivity to Parietaria extract (Allergovit®) in all patients. The graph represents the ELISA reactivity when the SD of each sample was not considered.
patient sera were reactive when the OD value (minus SD) was above the threshold of 0.132 (data not shown). High specific IgE ranged between 0.091 and 1.47 OD when the SD of each sample was not considered and between 0.082 and 1.407 OD when SD was included. No reaction in the patient sera was observed when the ELISA plates were coated with Depigoid®.

Sera of the 10 patients (1, 7, 8, 9, 12, 14, 16, 19, 21 and 22) with the highest reactivity to the sample (i.e. highest OD values identified by the ELISA) (Fig. 2) were selected to test cross-reactivity between allergens from *P. judaica* and *P. officinalis* by ELISA inhibition and were also used as a reference of the index of stimulation of the sera without inhibition. ELISA inhibition assay of the IgE binding to *P. officinalis* exhibited inhibition values >70% (ranging between 71.76 and 95.97%) in the sera of the 10 patients (Fig. 3), confirming cross-reactivity between the two *Parietaria* subspecies.

**Comparison of in vivo reactivities between two Parietaria subspecies in allergic patients sensitized to Parietaria.** All patients enrolled in the study exhibited double skin positivity against *P. judaica* and *P. officinalis* extracts, as assessed by the SPT (Table II). A parametric paired-sample Student's t-test identified greater wheal sizes for *P. judaica* compared with those for *P. officinalis* when measured by the longest wheal diameter (D; mean ± SD, 11.8±3.4 mm for *P. judaica* and 10.4±3.1 mm for *P. officinalis*; *P*=0.030), the longest diameters perpendicular to D (d; mean ± SD, 7.6±2 mm for *P. judaica* and 7±1.8 mm for *P. officinalis*; *P*=0.036) and (D+d)/2 (mean ± SD, 10±2.7 mm for *P. judaica* and 8.7±2.2 mm for *P. officinalis*; *P*=0.002). Positive skin reactivity was also observed for the positive control (histamine) with a mean ± SD of 8.8±2.4 mm for D, 6.5±1.5 mm for d and 7.7±1.7 mm for (D+d)/2. The negative control exhibited negative reactions in all patients.
Discussion

The identification and characterization of cross-reactive allergens provides clinicians with useful and practical guidance to optimize and improve diagnosis and immunotherapy treatment for patients with AR. The present study was conducted with the objective of assessing the cross-reactivity between two subspecies of the genus Parietaria, *P. judaica* and *P. officinalis*, in a sample of 24 patients diagnosed with AR and/or bronchial asthma due to *Parietaria* pollen, from the Levante region of the Spanish Mediterranean coast. For this purpose, immunotherapy extracts for the treatment of allergy to *Parietaria* (Allergovit® containing *P. officinalis*) were used. The final sample of patients was lower compared with the initially calculated number (30 patients); however, Bonura *et al.* (25) had previously identified cross-reactivity between the two *Parietaria* subspecies by using the rPar j 1 and rPar j 2 allergens in a sample of 25 patients.

The Bradford protein test confirmed that Allergovit®, in contrast to Depigoid®, contained proteins of *P. officinalis* extracts; it is widely known that a high variability exists in extracts of the same allergenic grass species produced by different companies, both qualitatively and quantitatively (27).

The results of the SPT in the present study revealed that all patients primarily sensitized to *P. judaica* pollen, as evidenced by significant skin reactivity and detected specific IgE levels, also exhibited significant reactivity to *P. officinalis* pollen. The *in vitro* ELISA test demonstrated that 87.5% of the patients were reactive to *P. officinalis* pollen, as confirmed by an OD ratio between 0.091 and 1.47, when the SD of the samples was not regarded; 79.1% of the patients still exhibited a significant OD ratio, between 0.082 and 1.407, when the SD of the individual samples was considered. In addition, 10 selected patients with the highest reactivity to the pollen extract (Allergovit®) exhibited ELISA inhibition values of IgE binding to *P. officinalis* >70%, confirming the cross-reactivity between the two *Parietaria* subspecies. Additionally, 2 patients reached values >95%. ELISA inhibition method instead of a direct binding test was selected in our study for the cross-reactive assessment of polyclonal antibodies, as this method is considered to be more reliable and to better discriminate between cross-reacting and non-cross-reacting IgE levels (28).

These results are comparable to the findings obtained by Patriarca *et al.* (26) in a sample of 30 Italian patients allergic to *Parietaria* pollen, and provide further evidence to confirm the complete cross-reactivity of *P. officinalis* and *P. judaica* extracts, as well as support the use of *P. officinalis* pollen extract in the diagnosis and immunotherapy of *Parietaria* allergy. In addition, compared with other cross-reactivity assessment studies, such as those associated with sensitization to pollen and vegetable foods presented by Aalberse (29) in their review, the results of the present study yielded higher cross-reactivity values.

The present study had certain limitations inherent to its retrospective design. Only patient data from the medical records as part of their routine medical care were collected, and total IgE levels, as well as specific IgE levels for *P. judaica*, were thus only available for a limited number of patients. In addition, quantification assays performed for detecting the levels of IgE specific for *P. judaica* and *P. officinalis* were not comparable, as they used different methods and detection ranges.

Another limitation was the use of a single *Parietaria* antigen concentration for the IgE binding inhibition assay to determine the subspecies cross-reactivity, as it was not possible to test inhibition of IgE binding variations using pollen proteins at different concentrations.

Finally, the results of the present study can only be generalized to the population of patients allergic to *Parietaria* from the Spanish Levante Coast area. Further similar studies implemented in other geographical zones should be conducted to verify these results.

In conclusion, the present study demonstrated that *P. judaica* and *P. officinalis* pollen extracts were highly cross-reactive, and that a unique *P. officinalis* pollen extract (Allergovit®) may be used for the diagnosis and immunotherapy of patients allergic to *Parietaria*.

Acknowledgements

Not applicable.

Funding

This study was funded by MERCK SLU.

Available of data materials

The datasets used or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

NC, II, AA and EEM substantially contributed to the acquisition, analysis and interpretation of data, drafted the manuscript, critically revised the manuscript for important intellectual content, and gave final approval of the version to be published. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Written informed consent was obtained from all study participants and ethics approval for this study was obtained from the Ethics Committee of Clinical Research at Hospital of Sagunto (Valencia, Spain).

Patient consent for publication

Not applicable.

Competing interests

Nataly Cancelliere and Ángel Ayuga are employees of MERCK SLU. The other the authors declare that they have no competing interests.
